CRBU - Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

2025-02-26 10:52:02 ET

Summary

• Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times.
• Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results.
• Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors.
• Key upcoming catalysts include interim data for Cema-cel’s ALPHA3 by mid-2025, and initial trials for ALLO-329 in autoimmune diseases starting in H1, 2025.

Overview

Allogene Therapeutics, Inc. ( ALLO ) is pioneering the development of allogeneic chimeric antigen receptor T-cells (CAR-Ts) for the treatment of cancer and autoimmune diseases. In other words, Allogene is genetically modifying immune cells (T-cells), obtained from healthy donors, in order to manufacture off-the-shelf universal CAR-Ts that recognize and eliminate malignant/altered cells causing cancer or autoimmune diseases.

CAR-T cells were discovered in 1993. Given its capacity to specifically target altered cells causing disease, while sparing other cells, scientists identified the enormous potential of CAR-Ts on the treatment of cancer and autoimmune diseases. Nowadays, there are a few CAR-T based therapies commercially available, indicated in second-line of treatment of various blood cancers, including Bristol Myers Squibb's (BMY) Breyanzi and Abecma, Gilead's (GILD) Yescarta and Tecartus, Novartis' (NVS) Kymriah, Johnson & Johnson's (JNJ) Carvykti, among others. The global CAR-T market size was estimated at $5.5 billion in 2024, and it is projected to grow at 39.6% CAGR, reaching up to $29 billion by 2029. The spectacular growth projections are partially based on the potential expansions into solid tumours, autoimmune disease, and the expectation of regulatory approvals for allogeneic CAR-Ts, which are aimed to be off-the-shelf therapies.

To date, all CAR-T treatments are autologous, meaning that the relevant cells have to be isolated from the patient, genetically modified in the laboratory, and then re-infused into the patient. The process can take from 2 weeks up to 6 months, and are personalized treatments. Hence, carrying a high cost, complex manufacturing process, among other challenges. In contrast, allogeneic cells are aimed to be mass-produced as universal therapies that once manufactured are readily available for the treatment of all patients. Thus, reducing cost and the period of time between diagnosis and infusion to only a couple of days, allowing patients to receive the appropriate treatment in a timely manner (see image below)....

For further details see: